Literature DB >> 21865889

Microtubule-severing ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation.

Eduarda Dráberová1, Stanislav Vinopal, Gerardo Morfini, Pei S Liu, Vladimíra Sládková, Tetyana Sulimenko, Matthew R Burns, Joanna Solowska, Kandan Kulandaivel, Jean-Pierre de Chadarévian, Agustin Legido, Sverre J Mörk, Jiří Janáček, Peter W Baas, Pavel Dráber, Christos D Katsetos.   

Abstract

We studied the expression and distribution of the microtubule-severing enzyme spastin in 3 human glioblastoma cell lines (U87MG, U138MG, and T98G) and in clinical tissue samples representative of all grades of diffuse astrocytic gliomas (n = 45). In adult human brains, spastin was distributed predominantly in neuronsand neuropil puncta and, to a lesser extent, in glia. Compared with normal mature brain tissues, spastin expression and cellular distribution were increased in neoplastic glial phenotypes, especiallyin glioblastoma (p < 0.05 vs low-grade diffuse astrocytomas). Overlapping punctate and diffuse patterns of localization wereidentified in tumor cells in tissues and in interphase and mitotic cells ofglioblastoma cell lines. There was enrichment of spastin in the leading edges of cells in T98G glioblastoma cell cultures and in neoplastic cell populations in tumor specimens. Real-time polymerase chain reaction and immunoblotting experiments revealed greater levels of spastin messenger RNA and protein expression in theglioblastoma cell lines versus normal human astrocytes. Functional experiments indicated that spastin depletion resulted in reduced cell motility and higher cell proliferation of T98G cells. Toour knowledge, this is the first report of spastin involvement incellmotility. Collectively, our results indicate that spastinexpression in glioblastomas might be linked to tumor cell motility, migration, and invasion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865889      PMCID: PMC3400501          DOI: 10.1097/NEN.0b013e31822c256d

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  58 in total

1.  The Golgi complex is a microtubule-organizing organelle.

Authors:  K Chabin-Brion; J Marceiller; F Perez; C Settegrana; A Drechou; G Durand; C Poüs
Journal:  Mol Biol Cell       Date:  2001-07       Impact factor: 4.138

Review 2.  Centrosome aberrations: cause or consequence of cancer progression?

Authors:  Erich A Nigg
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

3.  Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells.

Authors:  M Encinas; M Iglesias; Y Liu; H Wang; A Muhaisen; V Ceña; C Gallego; J X Comella
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

4.  Radial monolayer cell migration assay.

Authors:  Michael E Berens; Christian Beaudry
Journal:  Methods Mol Med       Date:  2004

5.  More microtubule severing proteins: more microtubules.

Authors:  Peter W Baas; Haruka Sudo
Journal:  Cell Cycle       Date:  2010-06-15       Impact factor: 4.534

6.  Aberrant localization of the neuronal class III beta-tubulin in astrocytomas.

Authors:  C D Katsetos; L Del Valle; J F Geddes; M Assimakopoulou; A Legido; J C Boyd; B Balin; N A Parikh; T Maraziotis; J P de Chadarevian; J N Varakis; R Matsas; A Spano; A Frankfurter; M M Herman; K Khalili
Journal:  Arch Pathol Lab Med       Date:  2001-05       Impact factor: 5.534

7.  Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia.

Authors:  I K Svenson; A E Ashley-Koch; P C Gaskell; T J Riney; W J Cumming; H M Kingston; E L Hogan; R M Boustany; J M Vance; M A Nance; M A Pericak-Vance; D A Marchuk
Journal:  Am J Hum Genet       Date:  2001-04-16       Impact factor: 11.025

8.  Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia.

Authors:  J Hazan; N Fonknechten; D Mavel; C Paternotte; D Samson; F Artiguenave; C S Davoine; C Cruaud; A Dürr; P Wincker; P Brottier; L Cattolico; V Barbe; J M Burgunder; J F Prud'homme; A Brice; B Fontaine; B Heilig; J Weissenbach
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

9.  The cellular and molecular pathology of the motor system in hereditary spastic paraparesis due to mutation of the spastin gene.

Authors:  Stephen B Wharton; Christopher J McDermott; Andrew J Grierson; Jonathan D Wood; Catherine Gelsthorpe; Paul G Ince; Pamela J Shaw
Journal:  J Neuropathol Exp Neurol       Date:  2003-11       Impact factor: 3.685

Review 10.  Cost of migration: invasion of malignant gliomas and implications for treatment.

Authors:  A Giese; R Bjerkvig; M E Berens; M Westphal
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

View more
  13 in total

Review 1.  Targeting Microtubules for Wound Repair.

Authors:  Rabab A Charafeddine; Joshua D Nosanchuk; David J Sharp
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-10-01       Impact factor: 4.730

2.  Mutant spastin proteins promote deficits in axonal transport through an isoform-specific mechanism involving casein kinase 2 activation.

Authors:  Lanfranco Leo; Carina Weissmann; Matthew Burns; Minsu Kang; Yuyu Song; Liang Qiang; Scott T Brady; Peter W Baas; Gerardo Morfini
Journal:  Hum Mol Genet       Date:  2017-06-15       Impact factor: 6.150

3.  Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MG.

Authors:  Dania Vázquez-Blomquist; Julio Raúl Fernández; Jamilet Miranda; Claudia Bello; José A Silva; Regla C Estrada; Lidia Inés Novoa; Daniel Palenzuela; Iraldo Bello
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 4.  Beyond taxol: microtubule-based treatment of disease and injury of the nervous system.

Authors:  Peter W Baas; Fridoon J Ahmad
Journal:  Brain       Date:  2013-06-27       Impact factor: 13.501

5.  Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.

Authors:  Y Otani; T Ichikawa; K Kurozumi; S Inoue; J Ishida; T Oka; T Shimizu; Y Tomita; Y Hattori; A Uneda; Y Matsumoto; H Michiue; I Date
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

Review 6.  Candidate Genes in Bull Semen Production Traits: An Information Approach Review.

Authors:  Mamokoma Cathrine Modiba; Khathutshelo Agree Nephawe; Khanyisile Hadebe Mdladla; Wenfa Lu; Bohani Mtileni
Journal:  Vet Sci       Date:  2022-03-23

7.  End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo.

Authors:  Raphael Berges; Nathalie Baeza-Kallee; Emeline Tabouret; Olivier Chinot; Marie Petit; Anna Kruczynski; Dominique Figarella-Branger; Stephane Honore; Diane Braguer
Journal:  Oncotarget       Date:  2014-12-30

Review 8.  Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia.

Authors:  Hans Zempel; Eva-Maria Mandelkow
Journal:  Mol Neurodegener       Date:  2015-12-21       Impact factor: 14.195

9.  Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.

Authors:  Lee Campbell; Ghaith Al-Jayyoussi; Robert Gutteridge; Nigel Gumbleton; Rosie Griffiths; Simon Gumbleton; Mathew W Smith; David F R Griffiths; Mark Gumbleton
Journal:  J Transl Med       Date:  2013-10-11       Impact factor: 5.531

10.  Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.

Authors:  Bettina Schlick; Petra Massoner; Angelika Lueking; Pornpimol Charoentong; Mirjam Blattner; Georg Schaefer; Klaus Marquart; Carmen Theek; Peter Amersdorfer; Dirk Zielinski; Matthias Kirchner; Zlatko Trajanoski; Mark A Rubin; Stefan Müllner; Peter Schulz-Knappe; Helmut Klocker
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.